share_log

Cantor Fitzgerald Initiates Coverage On Sorrento Therapeutics With Overweight Rating, Announces Price Target of $5

Benzinga Real-time News ·  Nov 2, 2022 09:28

Cantor Fitzgerald analyst Brandon Folkes initiates coverage on Sorrento Therapeutics (NASDAQ:SRNE) with a Overweight rating and announces Price Target of $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment